NeoStem is the first company to provide adult stem cell collection and
banking services to the general adult population, and is pursuing the research
and development of adult stem cell therapies, including therapies through the
use of very small embryonic-like stem cells, for regenerative purposes, both
in the U.S. and
ImmuneRegen has previously reported on the effects of Homspera on the differentiation of human adult stem cells, particularly into hematopoietic stem cells that are capable of becoming blood cells and are the foundation of the body's immune system. Very small embryonic-like stem cells are also found in adults but may have broader applications and are morphologically closer to embryonic stem cells in their potential. NeoStem has the ability to harvest very small embryonic-like stem cells from individual patients, representing a significant step toward overcoming the two major limitations in the development of stem cell therapies today -- the ethical dilemma regarding use of embryonic stem cells, and the immunological problems associated with using cells from a donor.
Under the collaboration, NeoStem has the right to execute an option agreement to negotiate an exclusive license to resulting technology.
"We look forward to working with the ImmuneRegen team to evaluate the
practical application of our exclusive VSEL(TM) technology and advance our
effort in the development of adult stem cell-based therapies," said
"Collaborating with NeoStem will allow ImmuneRegen to accelerate the
development of Homspera(R) for adult stem cell applications while, in parallel,
supporting other clinical applications of Homspera," said
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies
and building of a network of adult stem cell collection centers in the U.S.
and
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences
Holdings, Inc. (OTC Bulletin Board: IRBS), is a development-stage
biotechnology company focused on the research, development and licensing of
Homspera(R) and its derivatives. Homspera is an adult stem cell active
compound that in study results has been shown to regenerate and strengthen the
immune system and enhance wound healing. Additional intended uses being
developed include influenza as a stand-alone or combination therapy and as a
vaccine adjuvant. To advance its mission, the
Forward Looking Statements of ImmuneRegen
Statements about ImmuneRegen's future expectations, including statements
about the potential use and scientific results for its drug candidates,
science and technology, and all other statements in this press release other
than historical facts, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking
statements be subject to the safe harbors created thereby. These future
events may not occur as and when expected, if at all, and, together with
ImmuneRegen's business, are subject to various risks and uncertainties.
ImmuneRegen's actual results could differ materially from expected results as
a result of a number of factors, including the uncertainties inherent in
research and development collaborations, pre-clinical and clinical trials and
product development programs (including, but not limited to the fact that
future results or research and development efforts may prove less encouraging
than current results or cause side effects not observed in current pre-
clinical trials), the evaluation of potential opportunities, the level of
corporate expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic report on
Form 10-Q for the three months ended
Forward Looking Statements of NeoStem
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect NeoStem management's current expectations, as of the date
of this press release, and involve certain risks and uncertainties. Forward
looking statements include statements herein with respect to the success of
NeoStem's VSEL(TM) technology and the commercialization of stem cell programs
as well as the future of stem cell in medical treatment about which no
assurances can be given. NeoStem's actual results could differ materially from
those anticipated in these forward-looking statements as a result of various
factors. Factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's Annual Report on Form 10-K filed
with the with the Securities and Exchange Commission on
For more information, please contact: ImmuneRegen BioSciences Inc. Michael K. Wilhelm or John Fermanis Tel: +1-480-922-3926 Email: mwilhelm@immuneregen.com jfermanis@immuneregen.com Investor Contact: Redwood Consultants, LLC Tel: +1-415-884-0348 NeoStem, Inc. Robin Smith, CEO Tel: +1-212-584-4174 Email: rsmith@neostem.com Web: http://www.neostem.com CCG Investor Relations Lei Huang, Account Manager Tel: +1-646-833-3417 E-mail: lei.huang@ccgir.com Web: http://www.ccgir.com Crocker Coulson, President Tel: +1-646-213-1915 Email: crocker.coulson@ccgir.com
SOURCE NeoStem, Inc.